Quarterly revenue growth rates and guidance - market expects sustained 25-35% growth to justify valuation
Path to profitability metrics - operating margin trajectory and timeline to positive EBITDA
New product launches and FDA clearances for wound care formulations
Major hospital system or GPO (group purchasing organization) contract wins
low-to-moderate - Chronic wound care is relatively non-discretionary as it addresses medical necessity (diabetic ulcers, surgical wounds, pressure injuries). However, elective surgical volumes can decline in recessions, affecting surgical wound care product demand. The post-acute care market (skilled nursing, home health) is more resilient than acute care but faces reimbursement pressure. Medicare and Medicaid funding (70%+ of wound care reimbursement) provides stability, though budget constraints can impact facility purchasing decisions.
Rising interest rates create multiple headwinds: (1) Higher cost of debt service on the 7.7x D/E balance sheet, directly impacting cash flow; (2) Valuation multiple compression for unprofitable growth companies as investors demand higher risk premiums; (3) Potential tightening of credit availability for additional financing if needed to fund operations. The company's negative cash flow makes it vulnerable to financing market conditions. Lower rates would ease refinancing risk and support growth stock valuations.
Medicare/Medicaid reimbursement rate changes for wound care products and services - CMS policy shifts could compress end-market demand or pricing power
Regulatory pathway changes for wound care products (FDA reclassification from 510(k) to PMA could increase barriers but also competition)
Shift toward value-based care and bundled payments may pressure wound care product pricing as hospitals seek lower-cost alternatives
growth - The stock appeals to small-cap growth investors willing to accept near-term losses and high volatility for exposure to the expanding chronic wound care market. The 33% revenue growth, 90% gross margins, and large addressable market attract momentum investors, while the negative cash flow and 7.7x leverage deter value and income investors. Institutional ownership is likely limited given the $200M market cap and unprofitability. The -44% one-year return reflects de-rating of unprofitable healthcare growth stocks as interest rates rose in 2024-2025.
Trend
-7.9% vs SMA 50 · -7.0% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $62.6M $62.6M–$62.6M | — | -$0.64 | — | ±2% | Low1 |
FY2024 | $86.2M $85.9M–$86.5M | ▲ +37.6% | -$1.10 | — | ±5% | Low1 |
FY2025 | $103.0M $102.6M–$103.3M | ▲ +19.5% | $0.20 | — | ±0% | Low1 |
INSTITUTIONAL OWNERSHIP
SMTI News
About
With a focus on improving patient outcomes through evidence-based healing solutions and services, Sanara MedTech Inc. markets and distributes wound and skin care products and is seeking to offer wound care and dermatology virtual consultation services via telemedicine to physicians, hospitals, clinics, and all post-acute care settings. Sanara's products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgical Activated Collagen® to the surgical markets as well as the following products to the wound care market: BIAKŌS™ Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™ Antimicrobial Skin and Wound Irrigation Solution, and HYCOL™ Hydrolyzed Collagen Powder and Gel. The company is constantly seeking long-term strategic partnerships with a focus on products and technologies that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
SMTI◀ | $21.06 | -2.68% | $193M | — | +1897.4% | -3642.7% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.96% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.02% | — | 50.3 | +342120.9% | -4022.3% | 1500 |